Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Atezolizumab plus bevacizumab (ATZ + BV) is used for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B unresectable hepatocellular carcinoma (u-HCC) patients. However, the efficacy of ATZ + BV in various BCLC stage B conditions, especially the up-to-seven criteria in/out, has not been fully investigated. METHODS: We enrolled 83 BCLC stage B u-HCC patients with Child-Pugh class A who were treated with ATZ + BV as the first-line systemic chemotherapy in the study. All patients were evaluated for initial responses by dynamic computed tomography or magnetic resonance imaging after the initiation of ATZ + BV, and therapeutic efficacy was assessed. RESULTS: When stratified by up-to-seven criteria, progression-free survival (PFS) was significantly prolonged in patients with up-to-seven in (in vs. out: median 21.0 vs. 8.2 months, p = 0.006), and the Cox proportional hazard model showed that up-to-seven out/in was the significant factor contributing to PFS (out vs. in: HR 2.58, p = 0.007). We next evaluated PFS stratified by the maximum intrahepatic tumor diameter and number of intrahepatic tumors, which constitute the up-to-seven criteria. The number of tumors was a significant factor contributing to PFS (>7 vs. ≤7: HR 1.75, p = 0.040), but maximum tumor size was not (>5 cm vs. ≤5 cm: HR 1.19, p = 0.588). CONCLUSION: In BCLC stage B u-HCC patients treated with ATZ + BV, a high number of intrahepatic tumors were associated with poor PFS. Therefore, it may be better to consider additional treatment strategies in these patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
- Date Crossref
- 26/05/2025
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya City University Department of Gastroenterology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
Japanese Red Cross Nagoya Daini Hospital pays non établi dans la noticeÉtablissement de santé
-
Gifu Prefectural Tajimi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Kasugai Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Chukyo Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Toyokawa City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Nagasaki Rousai Hospital pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagoya City East Medical Center Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Asahi Rousai Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology and Metabolism — Nagoya City University, Japanese Red Cross Nagoya Daini Hospital et Department of Gastroenterology — Gifu Prefectural Tajimi Hospital, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.